Stay updated on Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial page.

Latest updates to the Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial page
- Check4 days agoChange DetectedRecruitment status is updated to show no participant enrollment, and new help sections plus a revised Intervention/Treatment heading with an updated revision tag (v3.6.0) were added.SummaryDifference0.2%

- Check11 days agoChange DetectedRevision tag updated from v3.5.4 to v3.5.5 on the page, indicating a minor update to the study record documentation.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe study record dates were updated, with new timestamps added (2026-05-22 and 2026-05-19) and older ones removed (2026-05-18 and 2026-04-24). These changes represent administrative updates to the trial record rather than modifications to the study content.SummaryDifference0.1%

- Check32 days agoChange DetectedA new revision 3.5.4 is added with recent date stamps (2026-05-18, 2026-04-24, 2026-04) and the note 'up to approximately 8 months'; older revision 3.5.3 and earlier dates/notes (2025-07-29, 2025-07-16, 'Minimum up to 6 months', 2025-07) were removed.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page now shows a newer ClinicalTrials.gov site revision (v3.5.3 instead of v3.5.0) in the footer, indicating an update to the site software rather than the underlying study record.SummaryDifference0.0%

- Check90 days agoChange DetectedReplaced Napoli, Italy, 80131 with Naples, Italy, 80131 in the locations list. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Epacadostat vs Standard of Care Clinical Trial page.